Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$0.14
EPS est.
$0.35
EPS surprise
-60.45%
1-day move
+4.18%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported earnings that missed expectations on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 4.18%. This could indicate that investors are optimistic about the company's future prospects despite the earnings miss, possibly due to the focus on ongoing clinical trials and product development.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.14 | N/A | -60.45% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future developments. They are focused on their clinical programs and maintaining operational efficiency.
Management highlighted ongoing efforts in clinical trials and product development.
They emphasized their commitment to advancing their pipeline despite current challenges.